• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝细胞癌手术入路的比较研究:中转手术与直接切除

A Comparative Study of Surgical Approaches for Hepatocellular Carcinoma: Conversion versus Direct Resection.

作者信息

Li Xinlin, Chen Kai, Feng Xu, Wu Xinhua, Qi Shiguai, Wang Qingmiao, Shi Zhengrong

机构信息

Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, People's Republic of China.

Department of Obstetrics and Gynecology, The Fifth People's Hospital of Chongqing, Chongqing, Chongqing, People's Republic of China.

出版信息

J Hepatocell Carcinoma. 2024 Oct 29;11:2101-2113. doi: 10.2147/JHC.S483397. eCollection 2024.

DOI:10.2147/JHC.S483397
PMID:39493264
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11531269/
Abstract

PURPOSE

The purpose of This study is exploring the intraoperative and perioperative differences between patients undergoing conversion surgery and those undergoing direct surgery, so as to improve preoperative preparation.

METHODS

The retrospective study was approved by an ethics review committee. A total of 232 patients with hepatocellular carcinoma who underwent surgical resection at the First Affiliated Hospital of Chongqing Medical University from September 2022 to December 2023 were included, comprising 210 operating patients and 53 conversion patients. Propensity score matching was employed for comparison in order to minimize bias.

RESULTS

The conversion group had more intraoperative bleeding (each P=0.001), longer operation time (P=0.033; PSM p=0.025), and higher intraoperative blood transfusion rate (p=0.001; PSM p=0.044). The incidence of perioperative complications, including perioperative ascites formation (p=0.011; PSM p=0.005), moderate to severe anemia (p=0.001; PSM p=0.002), postoperative blood transfusion (p=0.004; PSM p=0.036), and postoperative ICU transfer (p=0.041; PSM p=0.025), was higher in the conversion group compared to the operation group. The postoperative hospital stay (p=0.001; PSM p=0.003) was prolonged in the conversion group.

CONCLUSION

Post-conversion operations carry a higher risk of bleeding and are more likely to result in moderate to severe anemia and ascites formation in the perioperative period. However, the risk is reversible with adequate preoperative blood preparation and prompt postoperative symptomatic treatment. Conversion patients should be encouraged to undergo operating therapy when they can withstand surgical resection.

摘要

目的

本研究旨在探讨中转手术患者与直接手术患者在术中及围手术期的差异,以改善术前准备。

方法

本回顾性研究经伦理审查委员会批准。纳入2022年9月至2023年12月在重庆医科大学附属第一医院接受手术切除的232例肝细胞癌患者,其中手术患者210例,中转患者53例。采用倾向评分匹配法进行比较,以尽量减少偏倚。

结果

中转组术中出血更多(各P = 0.001),手术时间更长(P = 0.033;倾向评分匹配后P = 0.025),术中输血率更高(P = 0.001;倾向评分匹配后P = 0.044)。中转组围手术期并发症的发生率高于手术组,包括围手术期腹水形成(P = 0.011;倾向评分匹配后P = 0.005)、中度至重度贫血(P = 0.001;倾向评分匹配后P = 0.002)、术后输血(P = 0.004;倾向评分匹配后P = 0.036)和术后转入重症监护病房(P = 0.041;倾向评分匹配后P = 0.025)。中转组术后住院时间延长(P = 0.001;倾向评分匹配后P = 0.003)。

结论

中转手术后出血风险更高,围手术期更易出现中度至重度贫血和腹水形成。然而,通过充分的术前备血和及时的术后对症治疗,风险是可逆的。应鼓励中转患者在能够耐受手术切除时接受手术治疗。

相似文献

1
A Comparative Study of Surgical Approaches for Hepatocellular Carcinoma: Conversion versus Direct Resection.肝细胞癌手术入路的比较研究:中转手术与直接切除
J Hepatocell Carcinoma. 2024 Oct 29;11:2101-2113. doi: 10.2147/JHC.S483397. eCollection 2024.
2
[Comparison of the efficacy of robot assisted and thoracoscopic assisted thoracic surgery in non-small cell lung cancer].机器人辅助与胸腔镜辅助胸外科手术治疗非小细胞肺癌的疗效比较
Zhonghua Yi Xue Za Zhi. 2024 Sep 3;104(34):3221-3227. doi: 10.3760/cma.j.cn112137-20240226-00410.
3
Laparoscopic liver resection for hepatocellular carcinoma complicated with significant portal hypertension: A propensity score-matched survival analysis.腹腔镜肝切除术治疗合并重度门静脉高压的肝细胞癌:倾向评分匹配生存分析
Hepatobiliary Pancreat Dis Int. 2023 Aug;22(4):358-365. doi: 10.1016/j.hbpd.2022.03.012. Epub 2022 Mar 22.
4
Perioperative and short-term outcomes of laparoscopic liver resection for recurrent hepatocellular carcinoma: A retrospective study comparing open hepatectomy.复发性肝细胞癌腹腔镜肝切除的围手术期及短期结局:一项比较开放性肝切除术的回顾性研究
Front Oncol. 2022 Oct 17;12:956382. doi: 10.3389/fonc.2022.956382. eCollection 2022.
5
Perioperative and long-term survival outcomes of laparoscopic versus laparotomic hepatectomy for BCLC stages 0-A hepatocellular carcinoma patients associated with or without microvascular invasion: a multicenter, propensity score matching analysis.腹腔镜与开腹肝切除术治疗伴有或不伴有微血管侵犯的 BCLC 分期 0-A 期肝细胞癌患者的围手术期和长期生存结局:一项多中心、倾向评分匹配分析。
Hepatol Int. 2022 Aug;16(4):892-905. doi: 10.1007/s12072-022-10353-4. Epub 2022 Jun 15.
6
Outcomes of Laparoscopic Liver Resection for Patients with Multiple Hepatocellular Carcinomas Meeting the Milan Criteria: A Propensity Score-Matched Analysis.符合米兰标准的多发性肝细胞癌患者腹腔镜肝切除的疗效:倾向评分匹配分析
J Laparoendosc Adv Surg Tech A. 2019 Sep;29(9):1144-1151. doi: 10.1089/lap.2019.0362. Epub 2019 Aug 14.
7
Perioperative outcomes of uniportal versus three-port video-assisted thoracoscopic surgery in lung cancer patients aged ≥ 75 years old: a cohort study.≥75 岁老年肺癌患者单孔与三孔电视辅助胸腔镜手术围手术期结局的比较:一项队列研究。
BMC Surg. 2024 Jan 23;24(1):32. doi: 10.1186/s12893-024-02320-7.
8
Safety and feasibility of laparoscopic liver resection for hepatocellular carcinoma with clinically significant portal hypertension: a propensity score-matched study.腹腔镜肝切除术治疗伴有临床显著门脉高压症的肝细胞癌的安全性和可行性:一项倾向评分匹配研究。
Surg Endosc. 2021 Jul;35(7):3267-3278. doi: 10.1007/s00464-020-07763-6. Epub 2020 Jul 6.
9
Does metabolic syndrome affect perioperative outcomes in patients undergoing robotic hepatectomy? A propensity score-matched analysis.代谢综合征是否会影响接受机器人肝切除术患者的围手术期结局?倾向评分匹配分析。
Surg Endosc. 2023 Aug;37(8):6379-6384. doi: 10.1007/s00464-023-10047-4. Epub 2023 Apr 10.
10
Long-term perioperative outcomes of pure laparoscopic liver resection versus open liver resection for hepatocellular carcinoma: a retrospective study.纯腹腔镜肝切除术与开腹肝切除术治疗肝细胞癌的长期围手术期结局:一项回顾性研究。
Surg Endosc. 2020 Feb;34(2):796-805. doi: 10.1007/s00464-019-06831-w. Epub 2019 Jun 3.

本文引用的文献

1
Conversion therapy for advanced hepatocellular carcinoma in the era of precision medicine: Current status, challenges and opportunities.精准医学时代晚期肝细胞癌的转化治疗:现状、挑战与机遇。
Cancer Sci. 2024 Jul;115(7):2159-2169. doi: 10.1111/cas.16194. Epub 2024 May 2.
2
Safety and Survival Outcomes of Liver Resection following Triple Combination Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma.最初不可切除的肝细胞癌三联联合转化治疗后肝切除的安全性和生存结果
Cancers (Basel). 2023 Dec 17;15(24):5878. doi: 10.3390/cancers15245878.
3
Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy Combined a Tyrosine Kinase Inhibitor for Treatment of Large Hepatocellular Carcinoma.经动脉化疗栓塞术联合酪氨酸激酶抑制剂肝动脉灌注化疗治疗大肝癌。
Curr Cancer Drug Targets. 2023;23(7):564-571. doi: 10.2174/1568009623666230215142941.
4
Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With FOLFOX in Hepatocellular Carcinoma With Microvascular Invasion: A Multicenter, Phase III, Randomized Study.多中心 III 期随机对照研究:伴有微血管侵犯的肝细胞癌术后肝动脉灌注化疗 FOLFOX 方案的疗效观察。
J Clin Oncol. 2023 Apr 1;41(10):1898-1908. doi: 10.1200/JCO.22.01142. Epub 2022 Dec 16.
5
Transarterial chemoembolization plus apatinib with or without camrelizumab for unresected hepatocellular carcinoma: A two-center propensity score matching study.经动脉化疗栓塞联合阿帕替尼(联合或不联合卡瑞利珠单抗)治疗不可切除肝细胞癌:一项两中心倾向评分匹配研究
Front Oncol. 2022 Nov 10;12:1057560. doi: 10.3389/fonc.2022.1057560. eCollection 2022.
6
Hepatocellular carcinoma.肝细胞癌
Lancet. 2022 Oct 15;400(10360):1345-1362. doi: 10.1016/S0140-6736(22)01200-4. Epub 2022 Sep 6.
7
Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve.阿替利珠单抗联合贝伐珠单抗治疗不可切除的晚期肝细胞癌的初步疗效及肝储备功能的重要性。
Cancer Med. 2023 Feb;12(3):2646-2657. doi: 10.1002/cam4.5145. Epub 2022 Aug 14.
8
Chinese expert consensus on neoadjuvant and conversion therapies for hepatocellular carcinoma.中国肝癌新辅助和转化治疗专家共识。
World J Gastroenterol. 2021 Dec 21;27(47):8069-8080. doi: 10.3748/wjg.v27.i47.8069.
9
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.BCLC 策略用于预后预测和治疗推荐:2022 年更新版。
J Hepatol. 2022 Mar;76(3):681-693. doi: 10.1016/j.jhep.2021.11.018. Epub 2021 Nov 19.
10
Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice.贝伐珠单抗联合阿替利珠单抗治疗不可切除肝细胞癌的真实世界实践:日本患者的早期经验。
Invest New Drugs. 2022 Apr;40(2):392-402. doi: 10.1007/s10637-021-01185-4. Epub 2021 Sep 29.